Organogenesis (NASDAQ:ORGO) Issues Earnings Results, Misses Expectations By $0.05 EPS

Organogenesis (NASDAQ:ORGO) released its quarterly earnings results on Thursday. The company reported ($0.23) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.05), FiscalAI reports. The company had revenue of $45.46 million during the quarter, compared to analyst estimates of $52.10 million. Organogenesis had a negative net margin of 19.94% and a negative return on equity of 23.89%.

Here are the key takeaways from Organogenesis’ conference call:

• Third-quarter net product revenue fell 70% year over year, though it rose 6% sequentially. The company lowered its 2026 revenue outlook to $179 million–$200 million and described the market recovery as more measured than previously expected.
• Organogenesis said it gained market share, with claims data indicating its share increased more than 30% versus Q1, and reported sequential sales growth across Advanced Wound Care and Surgical & Sports Medicine. Management believes the market has bottomed, while acknowledging that low-cost inventory and ongoing customer uncertainty may continue to affect recovery.
• The company reported a $29.6 million GAAP net loss and had $26.9 million in cash and restricted cash at quarter-end, down from $94.3 million at year-end 2025. Management expects further sequential improvement in adjusted EBITDA, but positive adjusted EBITDA in Q4 is anticipated only at the high end of its outlook.
• The FDA review of Amnuvx faces a longer timeline after the agency identified 18 items requiring remediation at the Norwood facility and requested additional clinical information. The company expects remediation to finish by September 2027, estimates an $8 million total cost, and said the PDUFA target date will be extended from April 2027.

Organogenesis Price Performance

Shares of NASDAQ:ORGO traded down $0.03 during trading on Thursday, reaching $0.84. The stock had a trading volume of 708,108 shares, compared to its average volume of 1,074,363. The company has a debt-to-equity ratio of 0.07, a quick ratio of 3.00 and a current ratio of 3.52. Organogenesis has a 1-year low of $0.73 and a 1-year high of $7.08. The stock has a market cap of $108.08 million, a PE ratio of -0.98 and a beta of 1.48. The business has a fifty day moving average price of $1.28 and a 200-day moving average price of $2.32.

Analyst Upgrades and Downgrades

ORGO has been the topic of several research analyst reports. Truist Financial dropped their target price on shares of Organogenesis from $3.00 to $2.00 and set a “hold” rating on the stock in a research report on Friday, August 7th. Weiss Ratings downgraded shares of Organogenesis from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Monday, October 19th. Finally, Wall Street Zen raised shares of Organogenesis from a “strong sell” rating to a “sell” rating in a research note on Saturday, September 19th. Two research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Reduce” and an average target price of $4.33.

Organogenesis Company Profile

Organogenesis Holdings Inc is a biotechnology company that develops, manufactures and commercializes products intended to support tissue regeneration and wound healing. The company serves the advanced wound care and surgical and sports medicine markets, with a focus on therapies that help manage complex wounds and support the repair of damaged tissue.

Its product portfolio includes bioengineered skin substitutes and other biologic products, such as Apligraf, Dermagraft, NuShield, Affinity and NuCel.